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1. Introduction  
The endothelium is a continuous cellular monolayer lining the interior of the blood 
vessels and heart. Classically considered to exert its actions only as a mechanical barrier, 
also plays important roles in vascular physiology. Endothelium participates in numerous 
metabolic and regulatory functions such as the control of primary hemostasis, blood 
coagulation and fibrinolysis, interaction with lipoprotein metabolism, platelet and 
leukocyte interactions with the vessel wall, presentation of histocompatibility antigens, 
regulation of vascular tone and growth, and of blood pressure. The endothelium exerts 
these actions through the release of such vasoactive compounds as prostacyclin, 
thromboxane A2, nitric oxide (NO), bradykinin, endothelin, angiotensin, and free radicals 
that control the functions of vascular smooth muscle cells and of circulating blood cells 
(Ross, 1999; Vapaatalo & Mervaala, 2001).  
The integrity and functionality of the arterial endothelium play a crucial role in the 
physiology of circulation (Filipe et al., 2008) and, as a consequence, in preventing the 
development of cardiovascular diseases, whose genesis is currently considered a 
consequence of the anatomical and functional disruption of the endothelium 
(Spyridopoulos et al., 1997). When the ability of the endothelial cells to release relaxing is 
reduced, and in particular if the propensity to produce contractile factors is enhanced, 
endothelial dysfunction appears as a first step in the sequence of events that leads to 
atherosclerosis and coronary disease. Thus, no single mechanism is responsible for all 
endothelium dependent responses and their modulation by pathophysiological states 
leads to endothelial dysfunction characterized by an imbalance in endothelial regulators 
(Vanhoutte et al., 2009).  
Clinical and experimental data support the consideration of endothelium as a target for 
estradiol and other sexual hormones. A number of studies have demonstrated a 
favourable profile for estrogens in both experimental animal, as well as in in vitro models 
(Turgeon et al., 2006). However, the protective effect detected in a considerable number of 
observational clinical studies (Barrett-Connor & Grady, 1998) has not been confirmed by 
randomized placebo-controlled trials (Hulley et al., 1998; Grady et al., 2002), which 
described clinical complications, such as thrombosis in veins and coronary arteries, 
developed in postmenopausal women during the administration of exogenous hormones 
(Cano et al., 2007). 
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A number of studies have demonstrated that estrogens exert significant benefits on the 
cardiovascular system, and at least a part of these benefits are attributed to the direct effect of 
estradiol on vascular endothelial cells (Mendelsohn & Karas, 1999; Rubanyi et al., 2002; Sader 
& Celermajer, 2002). Estradiol is able to stimulate endothelial NO production through several 
mechanisms, including increased expression of NO synthases (mainly endothelial NO 
synthase), increased L-arginine availability, non-genomic activation of second messengers  
(Simoncini, 2009), translocation to intracellular sites, modulation of NO degrading sites (Tostes 
et al., 2003), and modulation of endogenous antagonist levels (Monsalve et al., 2007).  
Additionally, estradiol is able to exert antioxidant actions on endothelium (Shwaery et al., 
1998; Hermenegildo et al., 2002), to modulate the renin-angiotensin system (Farhat et al., 
1996; Alvarez et al., 2002), and to decrease endothelin-1 production (Mikkola et al., 1995; 
Akishita et al., 1998). Furthermore, estradiol regulates endothelial cell expression of adhesion 
molecules (Caulin-Glaser et al., 1996; Abu-Taha et al., 2009). 
Estradiol has also been implicated on the regulation of prostanoids production in 
endothelial cells. Two main vascular prostanoids, prostacyclin and thromboxane A2, play an 
essential role in the maintenance of vascular homeostasis. Prostacyclin is a vasodilator and 
an inhibitor of platelet aggregation; in contrast, thromboxane A2 is a vasoconstrictor and a 
promoter of platelet aggregation. As a consequence of their opposing roles, an imbalance in 
prostacyclin or thromboxane production has been implicated in the physiopathology of 
many thrombotic and cardiovascular disorders. In this chapter, we will discuss clinical and 
experimental data that document the endothelial effects of estradiol on prostanoid 
production and regulation, and their vascular consequences.  
2. Prostanoids in endothelium 
Prostanoids are unstable lipid mediators that, after intracellular biosynthesis, are released 
outside the endothelial cell. It is believed that prostanoids work mostly locally in an 
autocrine or paracrine way. Prostanoids are ubiquitous compounds that coordinate a wide 
variety of physiological and pathological processes via membrane receptors on the surface 
of target cells (FitzGerald, 2002). Prostanoids include prostaglandins (such as prostaglandins 
D2, E2, F2, F2ǂ, PGI2 –or prostacyclin-) and thromboxanes (such as TXA2) (Smith et al., 2000; 
Linton & Fazio, 2002). 
Prostanoids production is mainly regulated by the availability of free arachidonic acid and 
the activity of cyclooxygenases (COX). Release of arachidonate from cell membrane 
phospholipids is mediated through phospholipases, mainly phospholipase A2. Once 
arachidonate is released, it is sequentially converted to prostaglandins G2 and H2 by two 
COX isoenzymes (COX-1 and COX-2). The unstable prostaglandin H2 is then transformed 
into biologically active prostanoids by specific synthases in different cells. Prostaglandins 
interact with G-protein-coupled receptors, classified in function of their preferential affinity 
towards the five primary prostaglandins (Tsuboi et al., 2002) (Figure 1). 
COX isoenzymes (also known as prostaglandin endoperoxide synthases or prostaglandin H 
synthases) are the rate-limiting step in the formation of prostanoids from arachidonic acid 
and represent the main control mechanism for prostaglandin production (Smith et al., 2000). 
Both enzymes have similar biochemical activity in converting arachidonic acid to PGH2 in 
tissue or in recombinant enzyme systems (Vane et al., 1998). 
COX-1 and COX-2 are encoded by two different genes derived from human chromosomes 9 
and 1, respectively. In spite of there is a 60 - 65% homology between the isoforms within 
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species, the activity and the pattern of gene expression of these enzymes are differentially 
regulated (Davidge, 2001). 
 
Prostacyclin
(PGI2)
Thromboxanes 
(TXA2)
Phospholipase A2
Cyclooxygenase-1
or
Cyclooxygenase-2
Prostaglandins and thromboxanes 
synthases and isomerases
Membrane phospholipids
Arachidonic acid
Prostaglandin H2
Prostaglandin G2
Prostaglandins
(D2, E2, F2a)  
Fig. 1. Biosynthesis of prostaglandins and thromboxanes. 
COX-1 has been considered to be the constitutively expressed protein, while COX-2 is 
induced at sites of inflammation. Following that hypothesis, COX-1 would generate 
prostaglandins for physiological, housekeeping functions like gastrointestinal mucosal 
integrity and regulation of renal blood flow, while COX-2 would form the prostaglandins 
responsible for inflammatory symptoms (Smith et al., 2000; Parente & Perretti, 2003). 
But this separation of functions is so not clear. For instance, COX-2 is constitutively 
expressed in some regions of the central nervous system, and in renal and uterus tissues, 
suggesting it may play a role under physiologic conditions (Kim et al., 1999; FitzGerald, 
2002; Cheng & Harris, 2004). In fact, both COX-1 and COX-2 are involved not only in 
physiological, but also in pathological processes. The importance of this topic has impelled 
many outstanding reviews (Vane et al., 1998; Parente & Perretti, 2003; Cipollone et al., 2008; 
Vanhoutte, 2009). 
Regarding the vascular system, both isoenzymes are expressed in endothelium and smooth 
muscle cells. However, endothelial cells contain up to 20 times more COX than smooth 
muscle cells (DeWitt et al., 1983). As mentioned before for other organs, COX-1 has usually 
been considered in endothelium as the constitutive isoform, while COX-2 is induced by a 
number of cardiovascular risk factors, such as cytokines, cholesterol, lipoproteins, and 
hypoxia. Actually, both COX isoenzymes share characteristics of constitutive and inducible 
enzymes in endothelium. Shear stress induces COX-1 gene expression in human umbilical 
vein endothelial cells (HUVEC) (Doroudi et al., 2000), while clinical studies with a selective 
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inhibitor of COX-2 (celecoxib) have shown that this enzyme exerts control of most systemic 
prostacyclin production in healthy humans (McAdam et al., 1999). 
Although prostaglandins E2 and F2ǂ can contribute to vascular phenotype, two main 
prostanoids play an essential role in vascular physiology: thromboxane A2 and 
prostacyclin. On the one hand, in the cardiovascular system, thromboxane A2 is 
predominantly derived from platelet COX-1, but can also be produced by other cell types 
including the endothelial cells. The stimulation of thromboxane receptors elicits not only 
platelet aggregation and smooth muscle contraction, but also the expression of adhesion 
molecules and the adhesion and infiltration of monocytes/macrophages (Nakahata, 2008). 
As platelets are anucleate, there can be no induction of COX-2 enzyme synthesis 
(Patrignani et al., 1999). Thromboxane A2 can also be synthesized from endothelial cells 
(Sellers & Stallone, 2008). The third possibility is a transcellular formation of thromboxane 
A2 by platelets from prostaglandin H2 released by endothelial cells (Camacho & Vila, 
2000). Thromboxane A2 promotes irreversible platelet aggregation, vasoconstriction, and 
smooth muscle proliferation and, consequently, plays an important role as a mediator of 
not only haemostasis, but also of acute vascular occlusive events and atherogenesis 
(FitzGerald, 2002; Weir et al., 2003). 
On the other hand, in most blood vessels prostacyclin is the main prostanoid produced by 
endothelial cells, and the endothelium is its major source (Moncada & Vane, 1978). Both 
COX-1 and COX-2 isoenzymes contribute to the production of endothelial prostacyclin. By 
stimulating its preferential receptor, prostacyclin is a potent inhibitor of platelet adhesion to 
the endothelial cell surface and of platelet aggregation, and generally acts as an 
endothelium-derived vasodilator and an inhibitor of vascular smooth muscle migration and 
proliferation (Moncada & Vane, 1978; Fetalvero et al., 2007). 
Under physiological conditions, endothelial prostacyclin is a counterregulatory influence to 
platelet-derived thromboxane, and eicosanoids produced by the COX pathways generally 
induce vasorelaxation. Nevertheless, in some pathologic circumstances, such as oxidative 
stress and dyslipidemia, there may be an imbalance where COX-dependent vasoconstrictors 
and platelet aggregation become more predominant. Reactive oxygen species, such as 
superoxide anion and hydrogen peroxide are derived from multiple sources within 
inflammatory leukocytes and vascular tissues including NADPH oxidase, uncoupled 
endothelial and inducible endothelial NO synthase, xanthine oxidase, cyclooxygenases, 
lipoxygenases, cytochrome P450 monooxygenases and excess substrate utilization by 
mitochondria. Additionally, NO reacts with superoxide anion to form the extremely potent 
oxidant, peroxynitrite. Low concentrations of peroxinitrite selectively nitrate and inactivate 
prostacyclin synthase, which not only eliminates the vasodilatory, growth-inhibiting, 
antithrombotic, and antiadhesive effects of prostacyclin, but also increases release of the 
potent vasoconstrictor, prothrombotic, growth- and adhesion-promoting agents, 
prostaglandin H2 and thromboxane A2 being in general deleterious to vascular function 
(Zou et al., 2004; Schildknecht & Ullrich, 2009; Feletou et al., 2010).  
3. Estrogens actions on endothelium 
Estradiol is the most potent estrogen in humans, and exerts its actions mainly through 
binding and activation of estrogen receptors (ER). Two major subtypes of ER (ERǂ and ERǃ) 
have been identified. These receptors vary not only in their tissue distributions, but also in 
their agonist/antagonist profile of several compounds (Cano & Hermenegildo, 2000). Both 
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types of ER belong to the class of intracellular receptors classically defined as nuclear 
ligand-activated transcription factors. Activation of these receptors by the corresponding 
hormones affects gene expression by acting on specific sequences in the target genes, known 
as estrogen-response elements, and by modulating transcriptional events. 
The contribution of both receptors to the regulation of vascular effects is still under study. 
There is controversy about whether estrogenic effects are mediated through ERǂ, ERǃ or 
both. In the cardiovascular system, ERǂ and ERǃ have been identified by different 
techniques in the endothelium, smooth muscle cells and adventitia and on adrenergic nerve 
endings of arteries from various territories and several species, including humans (Karas et 
al., 1994; Kim-Schulze et al., 1996; Venkov et al., 1996; Register & Adams, 1998). Although it 
has been reported cultured endothelial cells do not express ERǂ (Toth et al., 2008), other 
investigators have demonstrated the presence of both ERǂ and ERǃ mRNA in endothelium 
(Wagner et al., 2001) and data from our group demonstrate the protein expression of both 
ERǂ and ERǃ in HUVEC (Sobrino et al., 2009; Sobrino et al., 2010).  
Although the relative significance of both ER subtypes in the vascular actions of estrogens is 
still under study, data from mice lacking either ERǂ (Pare et al., 2002; Arnal et al., 2010) or 
ERǃ (Zhu et al., 2002), and also from a non-functional mutation of ERǂ in a male patient 
(Sudhir et al., 1997), reveal an impaired vascular function. Therefore, ERǂ is probably critical 
for the production of estrogen vascular protective actions (Favre et al., 2010), but ERǃ may 
have relevant functions at the vascular level too (Simoncini et al., 2004). The changes in 
vascular cell gene and protein expression mediated by those ERǂ and/or ERǃ produce the 
classic, and better known, longer-term effects of estrogen (Cano & Hermenegildo, 2000). 
ER act in the nucleus as ligand-activated transcription factors that regulate gene expression 
in response to hormone binding. ER can also regulate vascular cell gene expression in the 
absence of estrogen following activation by growth factor signalling pathways, a process 
referred to as ligand-independent transcriptional activation. In addition, ER are able to 
signal rapidly (from seconds to minutes), in an apparently non-nuclear manner, resulting in 
downstream activation of specific kinases and their effectors molecules (Mendelsohn & 
Karas, 2010). 
The rapid effects of estrogens have been also explained by ER-independent mechanisms of 
action. For instance, the G protein-coupled receptor GPR30 has been proposed to be a 
third form of ER, although it is controversial whether GPR30 is a biologically-relevant ER 
or a collaborator in non-nuclear functions of the classical ER in certain contexts (Levin, 
2009). Moreover, even though GPR30 is expressed in certain endothelial cells, there is 
currently a lack of clear evidence of a role for the receptor in estrogen action in 
endothelium (Wu et al., 2011). 
Rapid actions of estradiol include several endothelial pathways, being the activity of 
endothelial nitric oxide synthase the most studied (Chow et al., 2010). Other signalling 
pathways acutely activated by estradiol in endothelium are several kinases, such as 
phosphotidylinositol 3-kinase (PI3K) (Razandi et al., 2000), protein kinase C (PKC) 
(Akarasereenont et al., 2000) and Rho-associated kinase (ROCK) (Simoncini et al., 2006; 
Oviedo et al., 2011). Rapid actions are responsible for the acute and potent vasorelaxation 
induced by estradiol both at physiological (Teoh et al., 2000; Tep-areenan et al., 2003) or 
supraphysiological (Naderali et al., 2001; Salom et al., 2002) concentrations, and it has been 
demonstrated in isolated vessels from animals such as rats (Tep-areenan et al., 2003), pigs 
(Teoh et al., 2000), rabbits (Salom et al., 2002), guinea pigs (Naderali et al., 2001), and even 
from human beings (Chester et al., 1995). 
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In addition, steroid hormone genomic and non-genomic effects may occur simultaneously 
and may act at different levels, revealing the complexity of estrogen regulation of vascular 
function (Tostes et al., 2003).  
4. Estrogens actions on prostanoids vascular regulation 
The actions of estrogens on prostanoids vascular production will be presented in two 
sections: first, those experimental data that are rapid in onset and short in duration (within 
minutes; “non-genomic” effects); second, those experimental data that are delayed in onset 
and prolonged in duration (require from hours to days to occur; “genomic” effects). 
4.1 Rapid effects of estrogens on prostanoids vascular production 
Physiological concentrations of estradiol cause a rapid stimulation of prostacyclin synthesis 
(within 15 min) in two types of cultured endothelial cells, ovine fetal pulmonary artery 
endothelial cells (PAEC) (Sherman et al., 2002) and HUVEC (Alvarez et al., 2002). In both 
cases, the use of the ER-antagonist ICI182780 reveals that the increased prostacyclin 
production is mediated through ER activation. In ovine PAEC, it seems mediated through 
ERǃ, since prostacyclin stimulation with estradiol was fully blocked by the ERǃ- antagonist 
RR-tetrahydrochrysene. Moreover, in ovine PAEC, the increased prostacyclin production is 
not related to changes in COX-1 or COX-2 protein abundance, thus reinforcing the 
implication of non-genomic mechanisms (Table 1) (Sherman et al., 2002). 
COX-pathway activity is involved in the acute relaxation afforded by estradiol. In rat 
mesenteric vessels and aorta, COX inhibition with indomethacin enhances the vasodilator 
potency of estradiol, suggesting an endogenous release of vasoconstrictor prostanoids (Tep-
areenan et al., 2003). But estradiol also indirectly affects vasoreactivity to contracting and 
relaxing substances. In epicardial porcine coronary arteries activation of ERǂ, but not of 
ERǃ, reduces thromboxane A2 vasoconstriction, indicating another indirect and vasodilator 
function of ERǂ (Traupe et al., 2007). Other data suggest that the estrogen-dependent 
constrictor prostanoid mechanism in the vascular wall may play an important role in the 
regulation of vascular tone in the female, in both normal and pathophysiological states. In 
that way, endogenous estrogen acts as an important regulator of constrictor prostanoid 
function in female rat aorta, involving the potentiation of COX-2 and thromboxane synthase 
expression in vascular wall (Li et al., 2008). 
Data from studies performed on postmenopausal women also supports the importance of 
COX-pathway in acute estrogen-induced vasodilation. Estradiol induces a rapid increase of 
cholinergic cutaneous vasodilation, which is eliminated in women treated for 6 weeks with 
celecoxib, suggesting that the COX-2 pathway plays a specific role in the rapid estradiol-
induced vasodilation in postmenopausal women (Calkin et al., 2002). 
Some studies have been performed at times that do not clarify whether the observed effects 
are genomic or non-genomic actions. Estrogen stimulates rat aortic endothelial cell release of 
prostacyclin after 1 hour of incubation without affecting COX-1 levels (Myers et al., 1996). 
That stimulation could be mediated by NO, since endogenous NO increased production of 
prostacyclin and thromboxane A2 in bovine coronary microvascular endothelial cells within 
1 hour, without affecting COX-1 or COX-2 expressions (Davidge et al., 1995). At molecular 
level, exposure of HUVEC for 40 min to estradiol significantly increases the expression of 
roughly 250 genes, measured by DNA microarray analysis. Among them, the COX-2 gene 
was the strongest up-regulated by estradiol. In fact, estradiol induced COX-2 gene 
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expression and new COX-2 protein synthesis by 40 and 60 min, respectively, and quickly 
stimulated the secretion of prostacyclin and prostaglandin E2 in an ER-dependent manner 
(Pedram et al., 2002). A similar, significant induction of COX-2 mRNA levels is obtained in 
human placental villous endothelial cells exposed to estradiol up to 1 hour, without an 
increased protein production (Su et al., 2009). 
 
Cell type Time 
E2 
(nM) 
Prostacyclin 
production 
COX-1 COX-2 Reference 
Rapid effects       
Ovine fetal PAEC 15 min 10 ↑ 52 % ņ ņ (Sherman et al., 2002) 
HUVEC 15 min 1 ↑ 57 % NA NA (Alvarez et al., 2002) 
HUVEC 30 min 1 ↑ 134 % NA NA (Alvarez et al., 2002) 
Delayed effects       
HUVEC 24 h 10 ↑ 26 % NA NA (Mikkola et al., 1995) 
HUVEC 24 h 0.1 ↑ 16 % NA NA (Mikkola et al., 1996) 
HUVEC 24 h 1 ↑ 78 % ņ ↑ (Akarasereenont et al., 
2000) 
HUVEC 24 h 1 ↑ 30 % ↑ ņ (Sobrino et al., 2009) 
HUVEC 24 h 10 ↑ 33 % ↑ ņ (Sobrino et al., 2010) 
Human coronary EC 24 h 100 ↑ 45 % NA NA (Mueck et al., 2002) 
Bovine coronary EC 24 h 1 Ņ 83 % ņ ņ (Stewart et al., 1999) 
Ovine fetal PAEC 48 h 10 ↑ 64 % ↑ NA (Jun et al., 1998) 
Table 1. Summary of estradiol effects on cultured cell production of prostacyclin. E2: 
concentration of estradiol in nM. Prostacyclin production is expressed as increased (↑) or 
decreased (Ņ) percentage of control values. COX-1 and COX-2 expression: increased (↑), 
decreased (Ņ), unchanged (ņ) or not available (NA). PAEC: pulmonary artery endothelial 
cells. HUVEC: human umbilical vein endothelial cells. EC: endothelial cells. 
4.2 Delayed (genomic) effects of estrogens on prostanoids vascular production 
Estrogen also exerts vascular delayed effects on the metabolism of prostaglandins and the 
activity of COX, as has been demonstrated in studies performed both in cultured cells, as 
well as in isolated vascular preparations.  
A time-course analysis performed in HUVEC, demonstrates that estradiol effects on 
prostacyclin production were evident only after 8 or 24 hours (10 and 1 nM estradiol, 
respectively), suggesting an ER-mediated genomic effect (Sobrino et al., 2010). Moreover, 
physiological concentrations of estradiol stimulate the production of prostaglandins, mainly 
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prostacyclin, in a variety of cultured endothelial cells, such as ovine fetal PAEC (Jun et al., 
1998), HUVEC (Mikkola et al., 1995; Mikkola et al., 1996; Akarasereenont et al., 2000; Sobrino 
et al., 2010), and human coronary endothelial cell (Mueck et al., 2002). In the vast majority of 
experiments, cells were exposed to estradiol during 24-48 hours, and the increase of 
prostacyclin above control values ranged from 16 % to 78 % (Table 1). 
In addition, it has been shown that estradiol stimulates production of prostaglandins in a 
variety of preparations of arteries, including ovine uterine arteries (Vagnoni & Magness, 
1998; Janowiak et al., 1998; Habermehl et al., 2000), mesenteric arteries from ovariectomized 
rats (Davidge & Zhang, 1998; Armstrong et al., 2002), rat cerebral blood vessels (Ospina et al., 
2002; Ospina et al., 2003), and aorta from ovariectomized monkeys (O'Sullivan et al., 2001). 
The increase of prostacyclin production is of a similar magnitude to that obtained with 
cultured endothelial cells. 
Concerning endothelial production of thromboxane A2 under estradiol, the literature 
indirectly suggests that estrogen would have a beneficial effect by decreasing the production 
of thrombogenic compounds. In men, there is a decrease in the formation of thromboxane 
A2  after the use of high dosage intra-muscular estrogen therapy (Henriksson et al., 1996). 
Moreover, the ratio of in vivo prostacyclin to thromboxane A2 formation increases 2-fold 
during estrogen replacement therapy (Mueck et al., 2001). Nevertheless, it has also been 
documented that estrogen increases platelet activation with the liberation of thromboxane 
A2 in women treated with hormone replacement therapy (Oliveira et al., 2005) and that 
estrogen enhances the constrictor prostanoid function in female rat aorta (Li et al., 2008). 
However, in cultured endothelial cells, thromboxane A2 production remains unchanged 
when measured  after exposure to estradiol (Sobrino et al., 2010). 
The regulatory role of estradiol on the biosynthesis pathway of prostanoids in endothelium 
(Figure 1) has been scarcely studied, with the only exception of COX-1 and COX-2 
expressions. Concerning the first enzyme, soluble phospholipase A2 is highly expressed in 
HUVEC and umbilical smooth muscle cells (Ost et al., 1998), but it does not appear to be 
regulated by estradiol. Phospholipase A2 expression remains unchanged after exposure to 
estradiol in HUVEC (Sobrino et al., 2010) or in human myometrial cells prepared from 
second trimester pregnant women (Korita et al., 2004). 
The roles of COX-1 and/or COX-2 isoenzymes in endothelial cells exposed to estradiol have 
been studied in some cases, and both enzymes have been implicated in estradiol effects. In 
ovine fetal PAEC after exposure to estradiol, both COX-1 mRNA and protein expressions 
were up-regulated  (Jun et al., 1998), whereas in HUVEC estradiol only induces COX-2 
expression protein (Akarasereenont et al., 2000). Genome-wide analysis performed in 
HUVEC exposed to estradiol for 24 hours demonstrated that COX-1 was among the 5 % of 
proteins which expression was changed more than 1.5 fold-times compared to controls, data 
that was verified by western blot analysis (Sobrino et al., 2009). 
Prostacyclin increased levels after vessel stimulation with estradiol have been mainly 
associated with enhanced expression of COX-1. In this way, COX-1 protein content is 
increased in rat (Ospina et al., 2002) and mice (Geary et al., 2001) cerebral blood vessels, and 
in ovine uterine arteries in response to treatment with estrogen (Rupnow et al., 2002). 
Indeed, COX-1 (but not COX-2) expression is increased in the endothelium of the ovine 
uterine artery during the follicular phase of the ovarian cycle and during pregnancy, where 
estrogen levels are highest (Janowiak et al., 1998; Habermehl et al., 2000). In spite of the 
classic consideration of COX-2 as an inducible enzyme, it seems that COX-2 does not 
contribute to the estradiol-increased prostacyclin production. Estrogen has even been found 
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to decrease COX-2 expression in mesenteric arteries from ovariectomized aged rats 
(Armstrong et al., 2002). 
However, similar experiments have occasionally produced contradictory results. Exposure 
of culture bovine coronary microvascular endothelial cells to physiological concentrations of 
estradiol for 24 hours reduced both prostacyclin and thromboxane A2 production (Stewart et 
al., 1999). In the case of whole tissue experiments, arteries respond in a different way to 
estradiol. This is the case of artery segments from different vascular beds (thoracic aorta, 
pulmonary artery, ear artery and coronary arteries) from adult male rabbits in which 
estradiol may cause both vasorelaxation and vasoconstriction (Saetrum et al., 2002). 
Moreover, in thoracic aorta the contractile effects of estrogen are mediated through the 
release of vasoconstrictor prostaglandins (Saetrum et al., 2002).  
These discrepancies could indicate a difference in the effects of estrogen depending on its 
previous serum concentration, the reproductive condition of the animal and/or the vascular 
bed being studied (Armstrong et al., 2002; Saetrum et al., 2002; Tostes et al., 2003). 
 
AA
PGH2
TXA2
ERα
↑COX-1
COX-2
TXAS
E2
PLA2
Membrane
phospholipids
↑PGIS
↑PGI2
 
Fig. 2. Estradiol-induced modifications on prostanoid pathway through ERǂ. Estradiol (E2), 
acting on ERǂ, increased cyclooxygenase-1 (COX-1) and prostacyclin synthase (PGIS) 
expression, resulting in an increased prostacyclin (PGI2) production. Phospholipase A2, 
cyclooxygenase-2 (COX-2) and thromboxane synthase (TXAS) expressions, along with 
thromboxane A2 production (TXA2), remained unchanged after exposure to estradiol. 
The regulatory actions of estradiol on the prostanoids biosynthesis pathway are mediated 
through ER activation. The use of ICI182780, a non-selective ER-antagonists, completely 
blocks estradiol-stimulated prostacyclin production in ovine fetal PAEC (Jun et al., 1998), 
HUVEC (Sobrino et al., 2009), and tamoxifen blocked it in HUVEC (Mikkola et al., 1995; 
Mikkola et al., 1996).  
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Moreover, data support a specific role for ERǂ on estradiol-stimulated prostacyclin 
production. Recently, selective ERǂ agonist 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1h-pyrazole 
(PPT), selective ERǃ agonist (diarylpropionitril; DPN), and selective ERǂ antagonist, methyl-
piperidino-pyrazole (MPP), have become available (Krom et al., 2007). With their use, it has 
been demonstrated that estradiol increased prostacyclin production, and COX-1 and 
prostacyclin synthase protein and gene expressions through ERǂ, whereas COX-2, 
phospholipases and thromboxane synthase expression remained unaltered (Sobrino et al., 
2010). The regulatory role of estradiol through ERǂ is supported by other studies. Estradiol 
increases levels of COX-1 in cerebral blood vessels from wild-type mice but was ineffective in 
ERǂ knockout mice (Geary et al., 2001) and also increases COX-1 expression through ERǂ in 
ovine endothelial cells transfected with the human COX-1 promoter (Gibson et al., 2005).  
5. Conclusion 
Remarkable progress has been made in elucidating the effects of estrogens on the vascular 
system, and the cellular and molecular mechanisms by which those effects are achieved. The 
analysis of published data supports estradiol increases prostacyclin vascular production in 
accordance with experimental and clinical research. This effect seems to be mediated mainly 
through ERǂ-dependent pathways which involve an increase in COX-1 and, in some cases, 
COX-2 activation and/or expression, and an augment in prostacyclin synthase expression, 
without affecting thromboxane A2 production. As a consequence, estradiol may reduce 
vascular tone and improve endothelium-dependent vasodilation (Figure 2).  
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